Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up to $2.90, with strong performance in oncology, immunology, and MedTech. Full-year guidance was raised for both sales and adjusted EPS, while significant product approvals and pipeline advancements were achieved.Original document: Johnson…
Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up to $2.90, with strong performance in oncology, immunology, and MedTech. Full-year guidance was raised for both sales and adjusted EPS, while significant product approvals and pipeline advancements were achieved.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
